ArticleTurkish journal of ophthalmology2025
Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye.
Article in Turkish journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Effectiveness of CARE-Based Spectacle Lenses for Myopia Control in a Turkish Pediatric Cohort.Vision (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to identify the key factors contributing to non-adherence in patients using 0.01% atropine for progressive myopia control in a specific single-center Turkish population and to propose strategies to enhance adherence. Materials and Methods: This retrospective study included 30 patients (mean age: 10.67±3.47 years; age range: 5-16 years; 14 males and 16 females) diagnosed with progressive myopia and prescribed 0.01% atropine treatment in our clinic between January and June 2021. All participants had discontinued 0.01% atropine treatment before completion. The reasons for discontinuation were analyzed using patient records and categorized into factors such as light sensitivity, difficulties with near vision, ocular or systemic side effects, the need for monthly eye drop renewal, and the long treatment duration. Data on patients' age, sex, treatment adherence, and reasons for discontinuation were collected. Statistical analyses were performed using IBM SPSS Statistics software. Results: The treatment discontinuation rate in our patient population was 14.92% (95% confidence interval: 10.23-19.61). The most common reasons for discontinuation were the need for monthly drop renewal (80%), long treatment duration (70%), and light sensitivity (60%). Discontinuation rates did not significantly differ by age group (p>0.05). The need for monthly renewal was more frequently reported as a barrier among female patients. Informed consent procedures had highlighted the long treatment duration and the need for monthly renewal, but these still represented barriers to adherence for some families. Conclusion: To improve adherence to 0.01% atropine treatment for progressive myopia in our patient population, patient education and enhanced support systems are essential. Implementing strategies to address challenges related to monthly renewal and providing better information about the long-term benefits of treatment could help increase adherence rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.